What is the Key Point for Designing HER2 Inhibitors?
暂无分享,去创建一个
Calvin Yu-Chian Chen | Hung-Jin Huang | Chien-Yu Chen | Da-Tian Bau | Ming-Hsui Tsai | Yuan-Man Hsu | Tin-Yun Ho | Yea-Huey Chang | Fuu-Jen Tsai | Chang-Hai Tsai | F. Tsai | M. Tsai | Chang-Hai Tsai | D. Bau | Y. Hsu | Hung-Jin Huang | T. Ho | Yea-Huey Chang | Calvin Yu‐Chian Chen | Chien-Yu Chen
[1] H. Fujii,et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma , 2005, British Journal of Cancer.
[2] A. D. Van den Abbeele,et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Jamil,et al. Homology models of the mutated EGFR and their response towards quinazoline analogues. , 2008, Journal of molecular graphics & modelling.
[4] D. Brattström,et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. , 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[5] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[6] Chao Zhang,et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. , 2007, Nature chemical biology.
[7] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[8] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.